drugset / Trial / NCT00203125

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

NCT00203125

Phase 3 Completed 55 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo

Timeline

Start
2000-10
Primary completion
2003-01
Completion
2003-01

Drugs

EvaluationDrugModalityDoseRoute
Background Rasagiline Small molecule 0.5 mg Oral
Background Rasagiline Small molecule 1 mg Oral

Indications